Wellness and performance
Bones & muscles
Hexarelin
Hexarelin is a synthetic peptide that triggers growth hormone release. Learn how it works, what human data exist, and why it is not FDA-approved.
- Reviewed by
- William Maish, MD MBA MPH, Clinical Product Lead
- Published
- October 5, 2026
- Last updated
- October 5, 2026
Key takeaway
Hexarelin is a potent synthetic ghrelin-mimic peptide that prompts the body to release growth hormone, sold in the wellness market for recovery and body composition. Human data are limited to short studies of growth hormone release, with no controlled trials supporting the marketed benefits, and repeated use appears to blunt its own effect. As of 2026 it is not FDA-approved and is banned in sport.
At a glance
| FDA status | Non-FDA-approved peptide (also known as examorelin) sold in the wellness/gray market |
| What it is | Potent ghrelin-receptor agonist / growth hormone-releasing peptide |
| Research | Human data are limited to short pharmacology studies; the marketed benefits are unproven |
| Sport | Prohibited by WADA at all times |
| Evidence strength | Low research |
What is hexarelin?
Hexarelin, with the generic name examorelin, is a synthetic six-amino acid peptide, structurally a methylated relative of GHRP-6. It is among the more potent growth hormone-releasing peptides for triggering growth hormone release. It is sold through wellness and "research peptide" channels and promoted for recovery and body composition, and it was never marketed as an approved drug.
How does it work?
Three features of its proposed mechanism stand out:
- It activates the growth hormone secretagogue (ghrelin) receptor on the pituitary to drive growth hormone pulses.
- It also binds a receptor called CD361 in cardiovascular tissue, which underlies preclinical interest in effects on the heart that may be separate from growth hormone.
- Studies report partial desensitization, in which the growth hormone response can diminish with repeated exposure.
The marketed benefits are extrapolated from the growth hormone rise. This describes the proposed mechanism, separate from proven outcomes.
Is it FDA-approved?
No. Hexarelin is not approved by the FDA and never reached market as a drug. It has been treated as not eligible for routine 503A compounding in the U.S. and is not approved for performance or anti-aging. In sport, growth hormone-releasing peptides including hexarelin (examorelin) are prohibited at all times under the WADA list.
What does the research show?
The human evidence is short pharmacology. According to PubMed, a study2 in healthy men found hexarelin produced a larger growth hormone rise than GHRH and acted in synergy with it, a hormone-level result rather than a clinical outcome. Its cardiovascular effects are described mainly in experimental models and reviews3. No controlled human trials support the marketed muscle, recovery, or anti-aging uses.
More for bones & muscles
Sources: a growth hormone pharmacology study (Arvat et al., Neuroendocrinology, 1995, DOI: 10.1159/0001268272) and a review of growth hormone secretagogues (Cao et al., Trends in Endocrinology & Metabolism, 2005, DOI: 10.1016/j.tem.2005.11.0043), both indexed on PubMed; and the WADA Prohibited List. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.